Streetbeat News

Analyst Ratings

SPY

Fitch Ratings forecasts that U.S. banks will experience lower expense growth in 2024, which will help mitigate margin pressure. This outlook is partly due to industry-wide job cuts, in addition to potential higher interest rates.

Portfolio Pulse from Benzinga Newsdesk

February 13, 2024 | 7:54 pm

ARKK

HOOD

TARK

Robinhood Markets, Inc (NASDAQ:HOOD) is experiencing slight trading fluctuations as it approaches its Q4 earnings release. After mixed Q3 results, the stock showed a bullish trend. Analysts predict a Q4 loss of 1 cent per share with revenues of $456.81 million. Mizuho analyst Dan Dolev maintains a Buy rating, raising the price target from $14 to $15. ARK Investment Management, led by Cathie Wood, has been buying Robinhood shares, indicating a positive outlook. The AXS 2X Innovation ETF (NASDAQ:TARK) offers a way to invest in Robinhood through a leveraged ETF that aims to return 200% of ARKK's daily performance, which includes Robinhood in its portfolio.

Portfolio Pulse from Melanie Schaffer

February 13, 2024 | 7:45 pm

PHM

PulteGroup's (NYSE:PHM) short interest has decreased by 26.87%, now standing at 3.95 million shares or 2.15% of its float. This decline in short interest could indicate a more bullish sentiment towards PHM among traders. Compared to its peers, PHM has a lower short interest percentage of float, with the average for its peer group being 4.98%. The reduction in short interest does not guarantee a price increase but suggests fewer shares are being shorted.

Portfolio Pulse from Benzinga Insights

February 13, 2024 | 7:45 pm

ALT

B Riley defended Altimmune (ALT) against a short report, highlighting factual inconsistencies in the report. This defense could influence investor perception and potentially impact ALT's stock price.

Portfolio Pulse from Benzinga Newsdesk

February 13, 2024 | 7:41 pm

PLCE

Children's Place Inc (NASDAQ:PLCE) shares dropped significantly in premarket trading after B Riley Securities downgraded the stock from Neutral to Sell and reduced the price target from $19 to $4. Analyst Jeff Lick highlighted the company's need for $50 million to $75 million in funding to maintain proper inventory and resource levels, warning that any new funding could be extremely dilutive to current equity. Lick also pointed out the risks of operating losses, especially in the company's seasonally weakest quarter, and a potential reinforcing cycle of distress.

Portfolio Pulse from Priya Nigam

February 13, 2024 | 7:27 pm

KALV

Needham analyst Serge Belanger maintains a Buy rating on KalVista Pharma (NASDAQ:KALV) and raises the price target from $22 to $35.

Portfolio Pulse from Benzinga Newsdesk

February 13, 2024 | 7:18 pm

CVS

Deep-pocketed investors are showing a bearish sentiment towards CVS Health (NYSE:CVS), with a notable shift in options trading activity. Benzinga's tracking revealed 8 extraordinary options activities, with a bearish majority among investors. The trading focuses on a price band between $35.0 and $76.0. Significant options trades include both calls and puts with varying sentiments and expiration dates. CVS Health, a major healthcare services provider, is currently trading down by -0.89% at $76.6. Analyst ratings in the last month have set an average target price of $85.5 for CVS.

Portfolio Pulse from Benzinga Insights

February 13, 2024 | 7:15 pm

KKR

Recent options activity for KKR & Co (NYSE:KKR) shows a bearish sentiment among investors, with 55% of trades being bearish. The options trades target a price range of $70.0 to $120.0. KKR, a major asset manager with $518.5 billion in AUM, is currently trading at $96.02, down by -1.64%. Analysts have issued mixed ratings, with a consensus target price of $96.5. The notable options activity and analyst ratings suggest a cautious outlook for KKR's stock in the short term.

Portfolio Pulse from Benzinga Insights

February 13, 2024 | 7:15 pm

ALT

LLY

NVO

Altimmune, Inc (NASDAQ:ALT) shares dropped after Kerrisdale Capital announced a short position, criticizing the potential of Altimmune's drug pemvidutide compared to competitors like Novo Nordisk's Ozempic and Eli Lilly's Mounjaro. Kerrisdale highlighted concerns over pemvidutide's efficacy, tolerability, and the challenging competitive landscape.

Portfolio Pulse from Adam Eckert

February 13, 2024 | 7:05 pm

TRMB

Piper Sandler analyst Clarke Jeffries upgraded Trimble Inc. (NASDAQ:TRMB) to Overweight from Neutral and raised the price target to $68 from $51, citing growth catalysts such as resegmentation, debt reduction, and share repurchases. Despite FY24 revenue guidance being below estimates, the underlying business is expected to grow ~8% y/y with ~27% EBITDA margins. The upgrade follows Trimble's Q4 earnings beat with 9% revenue growth and strong recurring revenue.

Portfolio Pulse from Nabaparna Bhattacharya

February 13, 2024 | 6:45 pm